Valeant Shares Plummet on 2016 Profit Forecast

The transcript discusses a company's financial struggles, including investor expectations and underlying business challenges. It highlights issues with product categories and market performance, particularly in dermatology and optomology. The company's significant debt and financial stability are examined, with concerns about its ability to service debt. Speculation about potential acquisition and market reactions is also covered, noting the impact of stock price fluctuations and leadership changes.

What concerns do analysts have regarding the company's financial stability?

What impact does the decline in stock price have on the company's acquisition potential?